"Dr. Robinson is an outstanding scientist most deserving of this distinction," said Don Hildebrand, President, CEO and Chairman of GeoVax Labs, Inc. "As a co-founder of GeoVax, Dr. Robinson has been instrumental in the success our company has achieved to date. Her leadership in HIV/AIDS vaccine research is invaluable. I believe her contributions will positively impact the lives of millions of people worldwide."
Dr. Robinson's recognition as AAAS Fellow was announced in the AAAS News & Notes section of the journal Science on 26 October 2007. She will be awarded an official certificate and pin on Saturday, February 16th at the Fellows Forum during the 2008 AAAS Annual Meeting in Boston.
About GeoVax Labs, Inc. (http://www.geovax.com)
GeoVax Labs, Inc. is a biotechnology company, established to develop, manufacture, license and commercialize human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents. GeoVax's vaccine technology is protected by 20 filed patent applications and issued patents.
GeoVax HIV/AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS), caused by the virus known as HIV-1, by vaccinating individuals prior to infection with the AIDS virus. In addition, GeoVax AIDS vaccines may be effective as therapeutics (treatment of people infected with AIDS virus). Studies evaluating these vaccines in already HIV/AIDS infected individuals are being planned.
GeoVax DNA and Recombinant MVA HIV/AIDS vaccines:
-- Use DNA vaccines to "prime" immune responses and MVA vaccines to
"boost" immune responses against the AIDS virus
|SOURCE GeoVax Labs, Inc.|
Copyright©2007 PR Newswire.
All rights reserved